Navigation Links
NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones
Date:5/21/2009

NuSil Technology announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones.

Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil Technology (http://www.nusil.com), a leading formulator and manufacturer of silicone compounds for the healthcare and pharmaceutical industries, announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones effective 1-May-2009. As part of the acquisition, NuSil will begin transitioning the manufacturing of seven key Simethicone products used in pharmaceutical applications. Financial details of the transaction were not disclosed.

"The Bluestar Pharmaceutical Simethicone products are a great complement to the current NuSil Simethicone product line. NuSil's 30 years experience working with healthcare-related materials, including silicones for drug delivery systems and long-term implants, provides us with the working regulatory knowledge needed to support the product line for our customers," said Richard Compton, CEO and co-founder of NuSil. "This acquisition, when combined with our ingestible Simethicone product line that we acquired from GE Advanced Materials in 2004, strengthens our position in the pharmaceutical industry as a leading Simethicone supplier with a broad product offering and global distribution capabilities."

Simethicones are wide spectrum antifoam and defoaming products which have been used successfully in various industries including pharmaceutical, food and cosmetics. In the pharmaceutical industry, Simethicones have shown efficacy as antifoams in processes such as biological fermentations and in the manufacture of antibiotics. Simethicones are also widely used as active pharmaceutical ingredients in anti-flatulent formulations. NuSil's current Simethicone products meet various monographs including the European Pharmacopeia for Simethicone and the United States Pharmacopeia for Simethicone Emulsion (contact NuSil for specific references). As part of this acquisition, NuSil will transfer the manufacturing of the Bluestar Silicones Pharmaceutical Simethicone business to NuSil's FDA registered facility in Bakersfield, California.

NuSil formulates standard and customized silicone products based on the vast, unique array of properties the material provides. Product quality is assured by the company's Quality System, which begins with an effective design protocol and continues up the supply chain from vendor qualification through re-inspection of finished product inventories.

For more information on NuSil's silicones for pharmaceuticals, call 805-684-8780 or visit http://www.nusil.com/simethicone.

About NuSil Silicone Technology
NuSil is a leading formulator of silicone compounds for healthcare, aerospace, electronics and other applications requiring precise, predictable materials performance. ISO-9001 certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and provides on-site, in-person application engineering support worldwide. More information about NuSil Technology can be found at http://www.nusil.com.

Media Contact
Stephanie Supina
NuSil Technology
805-684-8780 x221

# # #

Read the full story at http://www.prweb.com/releases/NuSil/Simethicone/prweb2447954.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
2. Recondo Technology Announces Two New Board Members
3. Nanotechnology May Simplify Antibiotic Treatment
4. SMS Technology Places Eye Health Educational Information at Hispanics Fingertips
5. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
6. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
7. Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records
8. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
9. NewCardio to Introduce Technology at Heart Rhythm Society Conference
10. Zila & Experts Testify at Congressional Hearing on Innovative Technology for Veterans; Urge Broader Use of ViziLite(R) Plus by VA for Oral Cancer Screening
11. Smart Phone, ePRO, and eDiary Technology Advances for Clinical Trials, Market Research, and Registries Reported by assisTek
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist Dr. John ... have never imagined back in 1991 that this journey would have taken me into ... last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more ... CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a more ... with fewer resources. It highlights the business’ principles, research and collaboration efforts in ...
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, ... the first in a new class of photodynamic cosmetics (PDC). , Allumera® is ... visibly reduce outward signs of aging, and minimize the appearance of pores – ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... VANCOUVER , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... the Bloom Burton & Co. Healthcare Investor Conference 2017 at the ... Edward Wright , Chief Executive Officer of the Company is ... Company,s CFO, Richard Bear and the Chairman of the ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
Breaking Medicine Technology: